Return to homepagePandemic Pact

THE IMPACT OF CAMOSTAT MESILATE ON COVID-19: A RANDOMISED, PLACEBO-CONTROLLED TRIAL

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $748,500

  • Funder

    Lundbeck Foundation

  • Principal Investigator

    N/A

  • Research Location

    Denmark

  • Lead Research Institution

    Aarhus University Hospital, Aarhus University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The researchers will investigate whether a known Japanese heartburn drug could slow down COVID-19 by reducing the spread of SARS-CoV-2 in the body. The drug has previously been proven to have an effect on SARS, which shares certain similarities with the new coronavirus, in mice. 180 patients in Danish hospitals will participate in the trial.